Literature DB >> 17976880

Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites.

Kelly J Skilbeck1, Jennifer N O'Reilly, Graham A R Johnston, Tina Hinton.   

Abstract

Post-mortem studies of the human brain indicate that certain GABA(A) receptor subtypes may be differentially altered in schizophrenia. Increased binding to the total population of GABA(A) receptors using [3H]muscimol is observed in the post-mortem schizophrenic brain, yet a proportion of these receptors which bind benzodiazepines and are labelled with [3H]flunitrazepam, show decreased or unaltered expression. Data from animal studies suggest that antipsychotic drugs alter GABA(A) receptor expression in a subtype selective manner, but in the opposite direction to that observed in schizophrenia. To broaden our understanding of the effects of antipsychotic drugs on GABA(A) receptors, we examined the saturation binding maximum (B(max)) and binding affinity (K(D)) of [3H]muscimol and [3H]flunitrazepam in the prefrontal cortex (PFC), hippocampus and thalamus of male SD rats that received a sucrose solution containing either haloperidol (1.5 mg/kg), olanzapine (6.5 mg/kg) or no drug daily for up to 28 days using quantitative receptor autoradiography. [3H]Muscimol binding density was increased most prominently in the PFC after 7 days, with larger and more prolonged effects being induced by the atypical antipsychotic drug olanzapine in subcortical regions. While no changes were observed in [3H]muscimol binding in any region after 28 days of drug administration, [3H]flunitrazepam binding density (B(max)) was increased for both antipsychotic treatments in the PFC only. These findings confirm that the subset of GABA(A) receptors sensitive to benzodiazepines are regulated differently from other GABA(A) receptor subtypes following antipsychotic drug administration, in a time- and region-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976880     DOI: 10.1016/j.pnpbp.2007.10.003

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  5 in total

Review 1.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

2.  Melanin-concentrating hormone is necessary for olanzapine-inhibited locomotor activity in male mice.

Authors:  Melissa J S Chee; Nicholas Douris; Avery B Forrow; Arnaud Monnard; Shuangyu Lu; Stephen E Flaherty; Andrew C Adams; Eleftheria Maratos-Flier
Journal:  Eur Neuropsychopharmacol       Date:  2015-06-03       Impact factor: 4.600

3.  GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.

Authors:  Elena Filatova; Anastasiya Kasian; Timur Kolomin; Ekaterina Rybalkina; Anelya Alieva; Lyudmila Andreeva; Svetlana Limborska; Nikolay Myasoedov; Galina Pavlova; Petr Slominsky; Maria Shadrina
Journal:  Front Pharmacol       Date:  2017-02-28       Impact factor: 5.810

Review 4.  Review of withdrawal catatonia: what does this reveal about clozapine?

Authors:  Matthew Lander; Tarun Bastiampillai; Jitender Sareen
Journal:  Transl Psychiatry       Date:  2018-07-31       Impact factor: 6.222

5.  Region-specific and dose-specific effects of chronic haloperidol exposure on [3H]-flumazenil and [3H]-Ro15-4513 GABAA receptor binding sites in the rat brain.

Authors:  Alba Peris-Yague; Amanda Kiemes; Diana Cash; Marie-Caroline Cotel; Nisha Singh; Anthony C Vernon; Gemma Modinos
Journal:  Eur Neuropsychopharmacol       Date:  2020-11-02       Impact factor: 4.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.